Zai Lab Limited (HKG:9688)

Market Cap	20.72B -32.5%
Revenue (ttm)	3.58B +15.3%
Net Income	-1.37B
EPS	-12.47
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,108,500
Average Volume	11,880,681
Open	18.16
Previous Close	18.16
Day's Range	17.99 - 18.56
52-Week Range	12.31 - 35.50
Beta	0.86
RSI	73.62
Earnings Date	May 8, 2026

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 1,784
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9688

Financial Performance

In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.

Financial numbers in USD